Page 12 - Reflections_dyslipidaemia_newsletter4_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #4 2023

Dyslipidaemia

The consensus panel recommends that Lp(a) should be
measured at least once in adults to identify those with high CV CLINICAL PEARLS FROM THE FACULTY
risk. Screening is also recommended in youth with a history of
ischemic stroke or family history of premature ASCVD or high
Lp(a) and no other identifiable risk factors.

In patients with high Lp(a) concentration, the consensus panel
recommends taking into account their global CV risk and Lp(a)
level. A high Lp(a) concentration should be interpreted in the
context of other risk factors and absolute global cardiovascular
risk, and addressed through intensified lifestyle and risk
factor management. The panel presents the recommended
intervention strategies as a function of total CV risk and WATCH
untreated Lp(a) concentration, ranging from lifestyle advice for PROF. LAVALLE COBO DISCUSS THE
lower CV risk scores and Lp(a) concentrations to lifestyle and RELEVANCE OF THE CONSENSUS
drug intervention (e.g., LDL-C, BP, and glucose) for higher CV STATEMENT ON CLINICAL PRACTICE.
risk scores and untreated Lp(a) concentrations.

Specific effective Lp(a)-lowering therapies are currently in Phase
II/III clinical trials, including novel antisense and small interfering CLICK HERE
RNA (siRNA) treatments that target apo(a) production. Early FOR THE LINK TO FULL ARTICLE
results seem promising.

TABLE OF CONTENTS